Gujarat Themis Biosyn delivered robust financial performance in the quarter ended June 2026, with standalone net profit rising 22.19% to ₹11.07 crore compared to ₹9.06 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this significant profit growth demonstrates the company's operational efficiency and market positioning during the quarter.
The company's sales revenue increased 22.08% to ₹43.79 crore in Q1 FY2026, up from ₹35.87 crore in the same period last year. As reported by Business Standard, this revenue growth indicates strong demand for the company's products and services, contributing to the overall profit expansion during the quarter. The latest data shows operating revenue grew to ₹438 crore in Q1 from ₹359 crore in the previous year, representing approximately 22.01% year-on-year growth.
Operating profit margin (OPM) stood at 47.50% in the June 2026 quarter, compared to 38.81% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this improvement in operating margins reflects enhanced operational efficiency and cost management during the quarter. The latest results show operating EBITDA margin expanded significantly to 47.48% in Q1 compared to 38.8% YoY, with operating EBITDA surging 49.64% to ₹208 crore from ₹139 crore in the previous year, highlighting robust profitability in the company's core business.
Profit before depreciation and tax (PBDT) increased 35% to ₹19.14 crore from ₹14.15 crore in the previous year's quarter. As reported by Business Standard, profit before tax (PBT) grew 25% to ₹15.17 crore compared to ₹12.12 crore in Q1 FY2025, indicating strong operational performance across all profitability metrics during the quarter. The latest consolidated results show consolidated net profit climbed to ₹111 crore in Q1 versus ₹91 crore in the previous fiscal year's quarter, with EBITDA growth outstripping revenue gains as operating leverage kicked in during the quarter.
